Comparison of the New Antihistamine Acrivastine (BW 825C) versus Cyproheptadine in the Treatment of Idiopathic Cold Urticaria

A double-blind, crossover trial with a new triprolidine derivative, acrivastine (BW 825C; 8 mg 3 times daily), cyproheptadine (4 mg 3 times daily) and placebo was carried out in 18 patients suffering from idiopathic cold urticaria. Acrivastine and cyproheptadine significantly (p